Beijing-headquartered Luzhu Biotech (02480) announced that all 11 resolutions proposed at the 12 June 2026 annual general meeting were approved by shareholders through a poll, each garnering 100.00% of the votes cast.

The meeting was attended—either in person or by proxy—by holders of 141.96 million H shares carrying voting rights, representing 71.37% of the total issued share capital excluding 3.54 million treasury shares, which were not entitled to vote.

Key approvals include:

• Financial and governance reports: The 2025 annual report, the Board’s 2025 work report, the Supervisory Board’s 2025 work report and the report of independent non-executive directors were all adopted.

• Profit distribution: Shareholders endorsed the 2025 profit distribution plan (details not disclosed in the filing).

• Auditor re-appointment: Deloitte Touche Tohmatsu will continue as the Company’s auditor for 2026, with the Board authorised to determine remuneration.

• Capital mandates: Special resolutions granted the Board general mandates to issue new shares, repurchase H shares, and extend the issuance mandate by the amount of shares repurchased.

• Financing flexibility: Shareholders approved applications for credit facilities and the provision of guarantees by the Group, alongside a change in the use of proceeds.

Tricor Investor Services acted as scrutineer, and all procedural requirements under PRC Company Law and the Company’s Articles of Association were met. All directors participated, with three attending in person and five via electronic means.